KhunSao personal page - To The Moon

KhunSao

KhunSao

No personal profile

55Follow

6Followers

0Topic

0Badge

2021-07-21

Good

Here Is The One-Word Reason Why JPMorgan Just Raised Its S&P Target To 4,600

2021-07-21

?

Cryptocurrency-related stocks soar in morning trading

2021-07-21

OMG ?

Airline stocks, Cruise Stocks rally continues in morning trading

2021-06-15

Pfizer hand up!

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up

2022-08-18

😁

Sorry, the original content has been removed

2022-08-18

$Tesla Motors(TSLA)$View on Tesla Motors(TSLA)BullishBearish

2021-08-31

?

Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis

2021-08-04

Thank u

Sorry, the original content has been removed

2021-07-08

Long termmmm

Why Apple Stock Climbed to a New High Today

2022-08-22

🙂👍[Miser]

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586405989757525","uuid":"3586405989757525","gmtCreate":1623320523144,"gmtModify":1626920407185,"name":"KhunSao","pinyin":"khunsao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":55,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.22","exceedPercentage":"80.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9996698018,"gmtCreate":1661155896736,"gmtModify":1676536463554,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"🙂👍[Miser]&nbsp;","listText":"🙂👍[Miser]&nbsp;","text":"🙂👍[Miser]","images":[{"img":"https://community-static.tradeup.com/news/549c37ce0378c06a55072835b38ab1de","width":"1080","height":"1653"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9996698018","isVote":1,"tweetType":1,"viewCount":2302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9998945889,"gmtCreate":1660923383543,"gmtModify":1676536424478,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"👍👏","listText":"👍👏","text":"👍👏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9998945889","repostId":"9991739229","repostType":1,"repost":{"id":9991739229,"gmtCreate":1660877159166,"gmtModify":1676536417098,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3569316529855154","idStr":"3569316529855154"},"themes":[],"title":"Market Updates : Nio","htmlText":"NIO: Delisting, Supply Constraints, And A Faltering Chinese Economy Aug. 17, 2022 8:10 AM ETNIO Inc. (NIO), NIOIF32 Comments9 Likes ‌<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>‌Summary NIO has been trading range-bound at the $20-level in recent months following a brief surge in easing COVID disruptions in China. While its fundamentals remain resilient, its valuation outlook continues to be constrained by risks pertaining to a potential delisting from the NYSE, ongoing supply constraints, and an unravelling Chinese economy. The following analysis will explore the different risks weighing on the \"fundamental\" and \"multiple\" factors that drive NIO's valuation prospects, as well as their related implications. Looking for more investing ideas like this one? Get them exclusively at Li","listText":"NIO: Delisting, Supply Constraints, And A Faltering Chinese Economy Aug. 17, 2022 8:10 AM ETNIO Inc. (NIO), NIOIF32 Comments9 Likes ‌<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>‌Summary NIO has been trading range-bound at the $20-level in recent months following a brief surge in easing COVID disruptions in China. While its fundamentals remain resilient, its valuation outlook continues to be constrained by risks pertaining to a potential delisting from the NYSE, ongoing supply constraints, and an unravelling Chinese economy. The following analysis will explore the different risks weighing on the \"fundamental\" and \"multiple\" factors that drive NIO's valuation prospects, as well as their related implications. Looking for more investing ideas like this one? Get them exclusively at Li","text":"NIO: Delisting, Supply Constraints, And A Faltering Chinese Economy Aug. 17, 2022 8:10 AM ETNIO Inc. (NIO), NIOIF32 Comments9 Likes ‌$NIO Inc.(NIO)$‌Summary NIO has been trading range-bound at the $20-level in recent months following a brief surge in easing COVID disruptions in China. While its fundamentals remain resilient, its valuation outlook continues to be constrained by risks pertaining to a potential delisting from the NYSE, ongoing supply constraints, and an unravelling Chinese economy. The following analysis will explore the different risks weighing on the \"fundamental\" and \"multiple\" factors that drive NIO's valuation prospects, as well as their related implications. Looking for more investing ideas like this one? Get them exclusively at Li","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991739229","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9998942621,"gmtCreate":1660923239965,"gmtModify":1676536424455,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9998942621","repostId":"9991603344","repostType":1,"repost":{"id":9991603344,"gmtCreate":1660818954651,"gmtModify":1676536404881,"author":{"id":"3527667626267411","authorId":"3527667626267411","name":"Value_investing","avatar":"https://community-static.tradeup.com/news/89ffffc59ff9ac9cb9cb74f596418d44","crmLevel":0,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667626267411","idStr":"3527667626267411"},"themes":[],"title":"6 Reasons Why I'm Strong Bullish on Alibaba","htmlText":"Chinese stocks have been having a rough time lately, with share prices once again approaching the lows of the March crash, like <a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a> ./<a href=\"https://laohu8.com/S/09988\">$Alibaba(09988)$</a> Looking at the faltering stock price, Chinese stock investors are&nbsp;heartbroken&nbsp;again.This time, will Alibaba rise to break the pressure&nbsp;level or move&nbsp;sideways&nbsp;in&nbsp;the bottom?I have six reasons to be fully bullish on Alibaba.1. Promising&nbsp;EarningsOn Aug. 4, Alibaba announced its latest quarterly earnings report. Revenue of 205.556 billion RMB, again exceeding Bloomberg analysts' consensus estimates.The domestic economy suffered a huge blow in the second quarter because of the serious pandemic.","listText":"Chinese stocks have been having a rough time lately, with share prices once again approaching the lows of the March crash, like <a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a> ./<a href=\"https://laohu8.com/S/09988\">$Alibaba(09988)$</a> Looking at the faltering stock price, Chinese stock investors are&nbsp;heartbroken&nbsp;again.This time, will Alibaba rise to break the pressure&nbsp;level or move&nbsp;sideways&nbsp;in&nbsp;the bottom?I have six reasons to be fully bullish on Alibaba.1. Promising&nbsp;EarningsOn Aug. 4, Alibaba announced its latest quarterly earnings report. Revenue of 205.556 billion RMB, again exceeding Bloomberg analysts' consensus estimates.The domestic economy suffered a huge blow in the second quarter because of the serious pandemic.","text":"Chinese stocks have been having a rough time lately, with share prices once again approaching the lows of the March crash, like $Alibaba(BABA)$ ./$Alibaba(09988)$ Looking at the faltering stock price, Chinese stock investors are heartbroken again.This time, will Alibaba rise to break the pressure level or move sideways in the bottom?I have six reasons to be fully bullish on Alibaba.1. Promising EarningsOn Aug. 4, Alibaba announced its latest quarterly earnings report. Revenue of 205.556 billion RMB, again exceeding Bloomberg analysts' consensus estimates.The domestic economy suffered a huge blow in the second quarter because of the serious pandemic.","images":[{"img":"https://community-static.tradeup.com/news/e0172e705e725661eb72343cebda65b4","width":"-1","height":"-1"},{"img":"https://community-static.tradeup.com/news/f654713b6bf7783801b88d62218f3227","width":"-1","height":"-1"},{"img":"https://community-static.tradeup.com/news/1b08435a9cedab6a2e119e8300910283","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991603344","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9991207497,"gmtCreate":1660835229421,"gmtModify":1676536408014,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$</a>😁","listText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$</a>😁","text":"$NIO Inc.(NIO)$😁","images":[{"img":"https://community-static.tradeup.com/news/1575ca228fef0d337032a27e639a4c96","width":"1080","height":"1839"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991207497","isVote":1,"tweetType":1,"viewCount":2608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9991206432,"gmtCreate":1660834735829,"gmtModify":1676536407912,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$</a>[Facepalm]&nbsp;","listText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$</a>[Facepalm]&nbsp;","text":"$NIO Inc.(NIO)$[Facepalm]","images":[{"img":"https://community-static.tradeup.com/news/957a56db6eb4329d034c7f506f1ef090","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991206432","isVote":1,"tweetType":1,"viewCount":2000,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9991206926,"gmtCreate":1660834649068,"gmtModify":1676536407894,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Great article! I would like to share it.","listText":"Great article! I would like to share it.","text":"Great article! I would like to share it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991206926","repostId":"9991674743","repostType":1,"repost":{"id":9991674743,"gmtCreate":1660833937488,"gmtModify":1676536407731,"author":{"id":"9000000000000469","authorId":"9000000000000469","name":"MortimerDodd","avatar":"https://static.tigerbbs.com/45889c069df88784e75b651f763a062a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000469","idStr":"9000000000000469"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TGT\">$Target(TGT)$</a>Target anticipates its operating margin rate will land in a range of around 6% during the back half of 2022. It’s undoubtedly comforting for TGT investors to know the company isn’t overly pessimistic for the remainder of the year.Will Target’s disappointing quarter set TGT stock up for third- and fourth-quarter earnings beats? It’s entirely possible if analysts and investors, given their disappointment today, maintain low expectations for Target.","listText":"<a href=\"https://laohu8.com/S/TGT\">$Target(TGT)$</a>Target anticipates its operating margin rate will land in a range of around 6% during the back half of 2022. It’s undoubtedly comforting for TGT investors to know the company isn’t overly pessimistic for the remainder of the year.Will Target’s disappointing quarter set TGT stock up for third- and fourth-quarter earnings beats? It’s entirely possible if analysts and investors, given their disappointment today, maintain low expectations for Target.","text":"$Target(TGT)$Target anticipates its operating margin rate will land in a range of around 6% during the back half of 2022. It’s undoubtedly comforting for TGT investors to know the company isn’t overly pessimistic for the remainder of the year.Will Target’s disappointing quarter set TGT stock up for third- and fourth-quarter earnings beats? It’s entirely possible if analysts and investors, given their disappointment today, maintain low expectations for Target.","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991674743","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1970,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9991201984,"gmtCreate":1660834245550,"gmtModify":1676536407844,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MSFT\">$Microsoft(MSFT)$</a>👍","listText":"<a href=\"https://ttm.financial/S/MSFT\">$Microsoft(MSFT)$</a>👍","text":"$Microsoft(MSFT)$👍","images":[{"img":"https://community-static.tradeup.com/news/c31bd8239f6b53a6c244d823acd2b762","width":"1080","height":"1839"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991201984","isVote":1,"tweetType":1,"viewCount":2576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9991209410,"gmtCreate":1660834128532,"gmtModify":1676536407809,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Great article! I would like to share it.","listText":"Great article! I would like to share it.","text":"Great article! I would like to share it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991209410","repostId":"2260387337","repostType":2,"repost":{"id":"2260387337","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1660833249,"share":"https://ttm.financial/m/news/2260387337?lang=en_US&edition=fundamental","pubTime":"2022-08-18 22:34","market":"us","language":"en","title":"US STOCKS-Wall St slips as weekly jobless claims edge lower","url":"https://stock-news.laohu8.com/highlight/detail?id=2260387337","media":"Reuters","summary":"(For a Reuters live blog on U.S., UK and European stock markets, click    or type LIVE/ in a news wi","content":"<html><body><p>(For a Reuters live blog on U.S., UK and European stock markets, click    or type LIVE/ in a news window)</p><p>   * Weekly jobless claims fall 2,000 to 250,000</p><p>   * Kohl's slashes 2022 forecasts</p><p>   * Indexes down: Dow 0.29%, S&amp;P 0.19%, Nasdaq 0.36%</p><p> (Updates prices to open)</p><p>   By Bansari Mayur Kamdar and Devik Jain</p><p>   Aug 18 (Reuters) - Wall Street's main indexes fell on Thursday after latest data suggested labor market conditions remain tight, while investors assessed minutes from the Federal Reserve's July meeting that indicated a less aggressive monetary policy tightening path.</p><p>   Eight of the 11 major S&amp;P 500 sectors declined in early trading, with consumer discretionary    and communication services    stocks leading losses.</p><p>   Labor Department data showed the number of Americans filing new claims for unemployment benefits fell last week and data for the prior period was revised sharply down.  </p><p>   \"Jobless claims fell again this week, showing the strength of the labor market,\" said Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.</p><p>   \"Unfortunately, what's good for the American worker is bad for the Fed's attempt to being inflation back down to 2%.\"</p><p>   Traders are still seeing a slightly greater probability of the Fed raising rates by 50 basis points in September, rather than a third 75 basis-point hike.   </p><p>   \"I would characterize yesterday's release of the minutes from last meeting really less hawkish,\" said Art Hogan, chief market strategist at B. Riley Wealth.</p><p>   Data showing softer-than-expected inflation in July has sparked a risk-on rally in Wall Street in the last few weeks, with focus now on the Fed's annual Jackson Hole symposium next week.</p><p>   Either a 50 bps or 75 bps rate hike in September would be a \"reasonable\" way to get short-term borrowing costs to a little over 3% by year end and a little higher than that in 2023, San Francisco Federal Reserve Bank President Mary Daly said on Thursday.  </p><p>   The Fed has lifted its benchmark interest rate by 225 bps so far this year to control four-decades high inflation.</p><p>   At 10:05 a.m. ET, the Dow Jones Industrial Average    was down 97.62 points, or 0.29%, at 33,882.70, the S&amp;P 500</p><p>  was down 8.11 points, or 0.19%, at 4,265.93, and the Nasdaq Composite    was down 46.37 points, or 0.36%, at 12,891.75.</p><p>   The tech-heavy Nasdaq    has bounced nearly 22% from its mid-June lows, while the benchmark S&amp;P 500    has risen 17%, supported by upbeat results from corporate America.</p><p>   However, retail earnings have been mixed so far, with encouraging reports from Walmart    and Home Depot    earlier this week, while Target's    profit slump dragged the retail sector    down 1.2% on Wednesday.</p><p>   Kohl's Corp    slid 4% after the retailer cut its full-year sales and profit forecasts.  </p><p>   Verizon Communications Inc    declined 2.5% after MoffettNathanson downgraded the telecom operator's shares.</p><p>   Declining issues outnumbered advancers for a 1.13-to-1 ratio on the NYSE and a 1.45-to-1 ratio on the Nasdaq.</p><p>   The S&amp;P index recorded three new 52-week highs and 29 new lows, while the Nasdaq recorded 26 new highs and 31 new lows.</p><p> (Reporting by Bansari Mayur Kamdar and Devik Jain in Bengaluru; Editing by Shounak Dasgupta)</p><p>((BansariMayur.Kamdar@thomsonreuters.com))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US STOCKS-Wall St slips as weekly jobless claims edge lower</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS STOCKS-Wall St slips as weekly jobless claims edge lower\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-08-18 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(For a Reuters live blog on U.S., UK and European stock markets, click    or type LIVE/ in a news window)</p><p>   * Weekly jobless claims fall 2,000 to 250,000</p><p>   * Kohl's slashes 2022 forecasts</p><p>   * Indexes down: Dow 0.29%, S&amp;P 0.19%, Nasdaq 0.36%</p><p> (Updates prices to open)</p><p>   By Bansari Mayur Kamdar and Devik Jain</p><p>   Aug 18 (Reuters) - Wall Street's main indexes fell on Thursday after latest data suggested labor market conditions remain tight, while investors assessed minutes from the Federal Reserve's July meeting that indicated a less aggressive monetary policy tightening path.</p><p>   Eight of the 11 major S&amp;P 500 sectors declined in early trading, with consumer discretionary    and communication services    stocks leading losses.</p><p>   Labor Department data showed the number of Americans filing new claims for unemployment benefits fell last week and data for the prior period was revised sharply down.  </p><p>   \"Jobless claims fell again this week, showing the strength of the labor market,\" said Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.</p><p>   \"Unfortunately, what's good for the American worker is bad for the Fed's attempt to being inflation back down to 2%.\"</p><p>   Traders are still seeing a slightly greater probability of the Fed raising rates by 50 basis points in September, rather than a third 75 basis-point hike.   </p><p>   \"I would characterize yesterday's release of the minutes from last meeting really less hawkish,\" said Art Hogan, chief market strategist at B. Riley Wealth.</p><p>   Data showing softer-than-expected inflation in July has sparked a risk-on rally in Wall Street in the last few weeks, with focus now on the Fed's annual Jackson Hole symposium next week.</p><p>   Either a 50 bps or 75 bps rate hike in September would be a \"reasonable\" way to get short-term borrowing costs to a little over 3% by year end and a little higher than that in 2023, San Francisco Federal Reserve Bank President Mary Daly said on Thursday.  </p><p>   The Fed has lifted its benchmark interest rate by 225 bps so far this year to control four-decades high inflation.</p><p>   At 10:05 a.m. ET, the Dow Jones Industrial Average    was down 97.62 points, or 0.29%, at 33,882.70, the S&amp;P 500</p><p>  was down 8.11 points, or 0.19%, at 4,265.93, and the Nasdaq Composite    was down 46.37 points, or 0.36%, at 12,891.75.</p><p>   The tech-heavy Nasdaq    has bounced nearly 22% from its mid-June lows, while the benchmark S&amp;P 500    has risen 17%, supported by upbeat results from corporate America.</p><p>   However, retail earnings have been mixed so far, with encouraging reports from Walmart    and Home Depot    earlier this week, while Target's    profit slump dragged the retail sector    down 1.2% on Wednesday.</p><p>   Kohl's Corp    slid 4% after the retailer cut its full-year sales and profit forecasts.  </p><p>   Verizon Communications Inc    declined 2.5% after MoffettNathanson downgraded the telecom operator's shares.</p><p>   Declining issues outnumbered advancers for a 1.13-to-1 ratio on the NYSE and a 1.45-to-1 ratio on the Nasdaq.</p><p>   The S&amp;P index recorded three new 52-week highs and 29 new lows, while the Nasdaq recorded 26 new highs and 31 new lows.</p><p> (Reporting by Bansari Mayur Kamdar and Devik Jain in Bengaluru; Editing by Shounak Dasgupta)</p><p>((BansariMayur.Kamdar@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","DOG":"道指ETF-ProShares做空","DJX":"1/100道琼斯","UDOW":"三倍做多道指30ETF-ProShares","SDOW":"三倍做空道指30ETF-ProShares","DDM":"2倍做多道指ETF-ProShares","BK4534":"瑞士信贷持仓","DXD":"两倍做空道琼30指数ETF-ProShares","BK4504":"桥水持仓"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2260387337","content_text":"(For a Reuters live blog on U.S., UK and European stock markets, click    or type LIVE/ in a news window)   * Weekly jobless claims fall 2,000 to 250,000   * Kohl's slashes 2022 forecasts   * Indexes down: Dow 0.29%, S&P 0.19%, Nasdaq 0.36% (Updates prices to open)   By Bansari Mayur Kamdar and Devik Jain   Aug 18 (Reuters) - Wall Street's main indexes fell on Thursday after latest data suggested labor market conditions remain tight, while investors assessed minutes from the Federal Reserve's July meeting that indicated a less aggressive monetary policy tightening path.   Eight of the 11 major S&P 500 sectors declined in early trading, with consumer discretionary    and communication services    stocks leading losses.   Labor Department data showed the number of Americans filing new claims for unemployment benefits fell last week and data for the prior period was revised sharply down.     \"Jobless claims fell again this week, showing the strength of the labor market,\" said Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.   \"Unfortunately, what's good for the American worker is bad for the Fed's attempt to being inflation back down to 2%.\"   Traders are still seeing a slightly greater probability of the Fed raising rates by 50 basis points in September, rather than a third 75 basis-point hike.      \"I would characterize yesterday's release of the minutes from last meeting really less hawkish,\" said Art Hogan, chief market strategist at B. Riley Wealth.   Data showing softer-than-expected inflation in July has sparked a risk-on rally in Wall Street in the last few weeks, with focus now on the Fed's annual Jackson Hole symposium next week.   Either a 50 bps or 75 bps rate hike in September would be a \"reasonable\" way to get short-term borrowing costs to a little over 3% by year end and a little higher than that in 2023, San Francisco Federal Reserve Bank President Mary Daly said on Thursday.     The Fed has lifted its benchmark interest rate by 225 bps so far this year to control four-decades high inflation.   At 10:05 a.m. ET, the Dow Jones Industrial Average    was down 97.62 points, or 0.29%, at 33,882.70, the S&P 500  was down 8.11 points, or 0.19%, at 4,265.93, and the Nasdaq Composite    was down 46.37 points, or 0.36%, at 12,891.75.   The tech-heavy Nasdaq    has bounced nearly 22% from its mid-June lows, while the benchmark S&P 500    has risen 17%, supported by upbeat results from corporate America.   However, retail earnings have been mixed so far, with encouraging reports from Walmart    and Home Depot    earlier this week, while Target's    profit slump dragged the retail sector    down 1.2% on Wednesday.   Kohl's Corp    slid 4% after the retailer cut its full-year sales and profit forecasts.     Verizon Communications Inc    declined 2.5% after MoffettNathanson downgraded the telecom operator's shares.   Declining issues outnumbered advancers for a 1.13-to-1 ratio on the NYSE and a 1.45-to-1 ratio on the Nasdaq.   The S&P index recorded three new 52-week highs and 29 new lows, while the Nasdaq recorded 26 new highs and 31 new lows. (Reporting by Bansari Mayur Kamdar and Devik Jain in Bengaluru; Editing by Shounak Dasgupta)((BansariMayur.Kamdar@thomsonreuters.com))","news_type":1,"symbols_score_info":{"161125":0.6,"513500":0.6,"SDOW":0.6,"DDM":0.6,"DJX":0.6,"UDOW":0.6,"DOG":0.6,"DXD":0.6}},"isVote":1,"tweetType":1,"viewCount":2273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9991677984,"gmtCreate":1660833943250,"gmtModify":1676536407739,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"😁","listText":"😁","text":"😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991677984","repostId":"2260389489","repostType":4,"isVote":1,"tweetType":1,"viewCount":2666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9991674468,"gmtCreate":1660833935456,"gmtModify":1676536407729,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Great article! I would like to share it.","listText":"Great article! I would like to share it.","text":"Great article! I would like to share it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991674468","repostId":"2260389489","repostType":4,"isVote":1,"tweetType":1,"viewCount":2055,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9991674849,"gmtCreate":1660833890083,"gmtModify":1676536407722,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991674849","repostId":"1127322828","repostType":4,"repost":{"id":"1127322828","kind":"news","pubTimestamp":1660814587,"share":"https://ttm.financial/m/news/1127322828?lang=en_US&edition=fundamental","pubTime":"2022-08-18 17:23","market":"us","language":"en","title":"After 2,240% Run, Tesla Visionary Leaves UK Fund Bleeding Money","url":"https://stock-news.laohu8.com/highlight/detail?id=1127322828","media":"Bloomberg","summary":"For years, he rode the likes of Amazon.com Inc. and Tesla Inc. to the moon, earning a reputation as ","content":"<div>\n<p>For years, he rode the likes of Amazon.com Inc. and Tesla Inc. to the moon, earning a reputation as the techno-visionary oracle of Edinburgh. Now, James Anderson, bull-market hero, has left behind a ...</p>\n\n<a href=\"https://www.bloomberg.com/news/features/2022-08-18/tesla-amazon-visionary-leaves-uk-fund-firm-baillie-gifford-down-100-billion\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After 2,240% Run, Tesla Visionary Leaves UK Fund Bleeding Money</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter 2,240% Run, Tesla Visionary Leaves UK Fund Bleeding Money\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-18 17:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/features/2022-08-18/tesla-amazon-visionary-leaves-uk-fund-firm-baillie-gifford-down-100-billion><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For years, he rode the likes of Amazon.com Inc. and Tesla Inc. to the moon, earning a reputation as the techno-visionary oracle of Edinburgh. Now, James Anderson, bull-market hero, has left behind a ...</p>\n\n<a href=\"https://www.bloomberg.com/news/features/2022-08-18/tesla-amazon-visionary-leaves-uk-fund-firm-baillie-gifford-down-100-billion\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/features/2022-08-18/tesla-amazon-visionary-leaves-uk-fund-firm-baillie-gifford-down-100-billion","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127322828","content_text":"For years, he rode the likes of Amazon.com Inc. and Tesla Inc. to the moon, earning a reputation as the techno-visionary oracle of Edinburgh. Now, James Anderson, bull-market hero, has left behind a precarious legacy.It’s been three months since Anderson, 63, retired from Baillie Gifford, the century-old Scottish money manager he transformed into anunlikely power-investorin global technology.Awkward timing, to say the least.Before Cathie Wood and Ark Invest, before crypto and “stonks,” Anderson began transforming Baillie Gifford’s prosaically namedScottish Mortgage Investment Trust— founded in 1909 to finance rubber plantationsand later Baillie Gifford’s flagship product — into one of the world’s top performing funds of its kind for a decade.Baillie Gifford offices in EdinburghPhotographer: Robert Ormerod/BloombergBut the tech stock meltdown has left the firm bleeding assets this year, losing a staggering 100 billion pounds ($122 billion) by the end of June. What was already a tall task for the next generation of the firm’s stock-pickers — convincing investors they can follow in Anderson's footsteps — has added a new hurdle: making the case that they should.Therecent market rallywill have helped, but changing course doesn’t appear to be an option. More than a dozen former and current employees and clients, most of whom spoke on the condition of anonymity in recent weeks, depict a firm that fell under the spell of Anderson’s success. A company partner who held no formal management position for years ended up driving Baillie Gifford’s entire approach to markets.What Anderson has left behind appears emblematic not only of this year’s market downturnbut also of the excesses that inflated a pandemic bubble in just about everything. Portfolio managers have been deployed to try to calm angsty clients.The uneasy mood was evident in mid-June as Scottish Mortgage investors gathered in London to hear what Baillie Gifford had to say about the drastic reversal of fortune.The crowd sat solemnly beneath dim chandeliers in a rented ballroom as Anderson’s successors, Tom Slater andLaurence Burns, called for patience, confident picks would pay off in the long run — that is, in 10 or even 20 years.Baillie Gifford famously piled into Amazon, Tesla and others that would soon catch fire in the bull market.Photographer: Rachel Jessen/BloombergSome attendees wondered out loud if Slater and Burns could deliver by following their old boss’s playbook. One asked if it would take 20 more years to figure out if Anderson really was a genius stock-picker or merely someone who lucked out in a bull market.“We are not sitting, looking into a crystal ball trying to predict what’s going to happen,” Slater said. “Wealth doesn’t come from predicting stuff but from a small number of exceptional companies.”It’s been quite a comedown. From its Edinburgh headquarters 3,200 miles from Wall Street, Baillie Gifford emerged in the 2000s and 2010s as one of theworld’s top stock-pickers,marketing the Anderson mystique and attracting ordinary investors and major pension funds across the US and Britain.Anderson set aside conventional investment metrics and staked his clients’ money on a relatively small number of risky, high-growth stocks. With a go-big-or-go-home ethos, he pressed portfolio managers to focus on sweeping, global themes, rather than investing geographically.And so, Baillie Gifford famously piled into Amazon, Tesla and others that would soon catch fire in the bull market. For years, the only investor who owned more of Tesla was Elon Musk. (Douglas Brodie,a partner and portfolio manager for another Baillie Gifford team, initially drove the Tesla investment in the early 2010s, but Anderson got most of the credit — and themedia attention).The results were extraordinary. From 2005 to its peak last year, Scottish Mortgage returned 2,240%.But what goes up usually comes down — in this case, down hard. With high-orbit tech stocks hurtling back to earth, Scottish Mortgage has plummeted 32% this year as of Aug. 16, its assets dropping to 14 billion pounds. All Baillie Gifford funds tracked by Bloomberg have fallen from 1% to 40% this year. Overall assets under management stood at 231 billion poundsat the end of June, versus 336 billion pounds at the start of the year.From Menlo Park to Shenzhen, Big Tech to startups, a pullback has followed a decade of giddy exuberance. SoftBank Group Corp.reporteda record 3.16 trillion yen ($23.4 billion) net loss on Aug. 8 after its Vision Fund, the world’s largest technology fund, got hammered.Given the shifting landscape, the question is when, or maybe whether, Baillie Gifford can regain its footing and help reinforce the business of stock picking that’s been undermined in recent years by the popularity of cheaper, index-tracking funds.James Anderson at the Allen & Co. Media and Technology Conference in Sun Valley, Idaho in 2019.Photographer: Patrick T. Fallon/BloombergIndeed, other big name investors came unstuck after stellar returns. Bill Miller, the manager whose unprecedented record of beating the Standards & Poor’s 500 Index made him aninvesting legend, couldn’t relive his past glories after a sharp turn in his fortunes.More dramatic was Neil Woodford’sfall from grace in the UK. The star money manager mesmerized investors for years with his performance. But following a poor run, clients startedpulling their cash, leading to the suspension of his flagship fund in 2019.Baillie Gifford is far more than one fund and has other strategies that don’t pursue the kind of returns that made Anderson a magnet for retail clients, who would flock to hear him speak at investor forums. But, over the time, the firm tilted toward his investing philosophy.Anderson, now chairman of Swedish investment companyKinnevik AB, waves off his influence. In an email, he dismissed the idea that his bull-market success and celebrity status came to define Baillie Gifford.“The influence was mostly because the high growth worked so well for a prolonged period and therefore — as is the way in finance — it attracted more attention and even imitation,” Anderson said of his sway over Baillie Gifford. “Maybe this always bothered me more than people realized.”In addition to Amazon and Tesla, big-name scores included Covid-19 vaccine maker Moderna Inc.Photographer: Guillaume Souvant/AFP/Getty ImagesBut during a tenure spanning four decades, he shook off the firm’s staid reputation and fundamentally changed its DNA. At a time when low-cost index funds were upending the investment business, he pushed the partnership in the opposite direction: He challenged portfolio managers to set aside indexes and instead find companies that would solve big problems. In addition to Amazon and Tesla, big-name scores included Covid-19 vaccine maker Moderna Inc.When markets were going their way, Anderson and his acolytes could steamroll most doubters. Unabashedly contrarian and sometimes quick-tempered, he sniffed at what he viewed as groupthink by bean-counting CFAs. Let others worry about quarterly results and P/E ratios. Anderson wanted to spot the super trends that would shape the future.People who questioned him or issued a negative report on one of his stock picks often found themselves on the losing side a heated argument, current and former employees say. Others learned to keep their mouths shut. To avoid office distractions, Anderson eventually stopped sharing his own research in Baillie Gifford’s library.Before long, Anderson and his crew stopped attending weekly investment meetings, dismissing the gatherings as a venue of low-brow short-termism. Baillie Gifford later made the confabs optional before binning them altogether.A scruffy, sometimes rumpled character with a professorial air — one former colleague recalls Anderson wearing an ink-stained shirt one day, another remembers his poorly knotted ties — Anderson came to be seen as the mad genius of Baillie Gifford. (In a telephone interview, Anderson conceded that he could be hot-tempered due to the stresses of the job.) His star rising, heenthralled everyday investors, scouted Silicon Valley and hung out with Jeff Bezos in Sun Valley.Insiders say that with Anderson gone there’s more room for flexibility, but Baillie Gifford is in so deep it might be hard to go back. Wholly owned by its roughly 50 partners, the firm has staked its future on the belief that it can spot the next big thing. Then, the thinking goes, it can do what Anderson did: Get in early — and hold on for the ride.Before July’s bounce, the ride has mostly gone in one direction: down. Baillie Gifford is a top-three holder of Moderna (down 22% year to Aug. 16); Shopify Inc. (down 68%); and Spotify Technology SA (down 41%). It’s also a major holder of Illumia Inc. (down 33%) and Peloton Interactive Inc. (down 58%), among others.Stock picks are only one problem. During the bull years, Anderson and his team also became go-to financiers for a range of tech startups. Flush with investor dollars, they seeded young businesses in hopes of reaping outsize returns once the companies went public.Unlisted companies accounted forroughly a thirdof Scottish Mortgage’s holdings at the end of June, according to company documents. The fund got in on the bull-market rush over the fledgling air-taxi business, picking up stakes inLilium NVand Joby Aviation Inc. It also bought into crypto financial-services company Blockchain.com and Northvolt AB, a Swedish battery developer.When or if many of those bets might pay off is anyone’s guess. One pick, biotech company Ginkgo Bioworks, went public last year, during the waning days of the craze over special purpose acquisition companies, or SPACs. Since then, the stock has fallen 53%.And while Anderson was the first to invest in private companies at Baillie Gifford, even more conservative investment trusts run by the firm have exposure to the asset class, albeit at much lower levels.Even Baillie Gifford insiders concede Anderson’s departure in April,telegraphedfor more than a year, came at a particularly fraught moment. The firm created a success story around Anderson and his investment philosophy and used that rosy narrative to market itself.James Budden, global head of marketing, acknowledged — with some limits — Anderson’s long-standing role in shaping Baillie Gifford. “He was a strong influence, but this took 20 years to play out,” said Budden, the only person Baillie Gifford made available to speak on the record. “Scottish Mortgage didn’t immediately become what it is today. Yes, he did define a lot of the investment thinking.”For better and worse, Anderson appears to have left a lasting mark. University graduates who join the firm’s training program no longer get schooled in financial statements as meticulously as they used to, people familiar with the matter said. People who’ve left recently say risk management could be improved.For years, the only investor who owned more of Tesla was Elon Musk.Photographer: Toru Hanai/BloombergBudden, the marketing chief, says trainees must still learn accounting but adds that success at Baillie Gifford takes vision, too. “We do have risk controls, though people think we don’t,” he said. “For us the biggest risk is finding the wrong companies and missing the big opportunities, but we also do proper risk analysis.”For now, Baillie Gifford seems hostage to the markets. Aninvestment teamcalled Global Alpha, createdby former senior partner Charles Plowden in 2005 as a counterweight to Anderson’s go-big philosophy, has weathered the storm better than Scottish Mortgage by investing in more, less volatile stocks.Global Alpha today manages 39 billion pounds, more than any other group in the firm. Yet, all the same, it still holds a crop of Anderson’s tech darlingslike Moderna and Tesla. The firm says any similarities between portfolios are unintentional and that each team does its own research.All the same, the 170-person client services team has been reemphasizingthe investment philosophy Anderson helped to build. Their line: This, too, shall pass — and Baillie Gifford will go on to greater heights as its bets pay off over coming decades. In webinars, letters and phone calls, the team has urged investors not to panic.The partnership keeps looking ahead. It plans to hire more people and move to a new glass-paneled, seven-story headquarters being built in a new development in Edinburgh’s West End. At a recent company-wide meeting, two senior partners said Baillie Gifford would stick to its guns. It was, they said, business as usual.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1005,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9991648835,"gmtCreate":1660832404829,"gmtModify":1676536407315,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>View on Tesla Motors(TSLA)BullishBearish","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>View on Tesla Motors(TSLA)BullishBearish","text":"$Tesla Motors(TSLA)$View on Tesla Motors(TSLA)BullishBearish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991648835","isVote":1,"tweetType":1,"viewCount":839,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881381704,"gmtCreate":1631292938408,"gmtModify":1676530523177,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Wowwww","listText":"Wowwww","text":"Wowwww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881381704","repostId":"883298049","repostType":1,"repost":{"id":883298049,"gmtCreate":1631241533075,"gmtModify":1676530506637,"author":{"id":"3510558082622800","authorId":"3510558082622800","name":"胖虎哒哒","avatar":"https://static.tigerbbs.com/75b95d9326c02813b7b87ba8c1eccb5a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3510558082622800","idStr":"3510558082622800"},"themes":[],"title":"小調查：iPhone13祕密泄露，你想換新機嗎？","htmlText":"隨着9月15日的蘋果特別活動日一天天的臨近，近期網上也涌現出諸多關於iPhone 13的信息。除了有新機的配置、價格爆料之外，最近還有媒體對iPhone用戶是否有升級iPhone 13的願意做了一期調查。據悉，該調查是由Savings開展，收集1500名iPhone用戶的意向。 根據調查結果顯示：其中僅有10%的用戶計劃入手iPhone 13，有着64%的用戶沒有升級計劃，此外，還有26%的用戶表示還沒做好決定。 對於這一調查結果，個人倒不會感到太大的意外。畢竟就目前的爆料的信息來看，iPhone 13相較於上一代並不會太多的提升，很可能只是將後置模組中的鏡頭改變了擺放位置，劉海屏縮小一些，並上全新的A15芯片。至於大家尤爲關心的120Hz高刷屏和大電池，大概率也只會在iPhone 13 Pro/ Pro Max身上出現。 此外，據烏克蘭人稱，iPhone 13系列將提供新的粉紅色、黑色和青銅色，存儲選項將與iPhone 12相同，除了 5.4 英寸和 6.1 英寸標準型號沒有 256GB 存儲選項之外被91mobiles發現的電子商務網站“KTC”聲稱已經透露了即將推出的設備的配置選項。 MacRumors 對黑色、青銅色和粉紅色 iPhone 13 型號的渲染。在iPhone 13迷你和iPhone 13顯然將繼續在六個顏色可供選擇：黑色，藍色，紫色，粉色，白色，和PRODUCT（RED）。這意味着粉紅色將取代 iPhone 12 陣容中的綠色。 另一方面，據稱iPhone 13 Pro和iPhone 13 Pro Max將繼續提供四種顏色選擇：黑色、銀色、金色和青銅色。這意味着黑色將取代iPhone 12 Pro系列中的石墨，而青銅色將取代太平洋藍。 再加上目前iPhone 12已經支持了5G網絡，所以對於iPhone 12用戶而言，新機確實談不上有太大的吸引力。下面","listText":"隨着9月15日的蘋果特別活動日一天天的臨近，近期網上也涌現出諸多關於iPhone 13的信息。除了有新機的配置、價格爆料之外，最近還有媒體對iPhone用戶是否有升級iPhone 13的願意做了一期調查。據悉，該調查是由Savings開展，收集1500名iPhone用戶的意向。 根據調查結果顯示：其中僅有10%的用戶計劃入手iPhone 13，有着64%的用戶沒有升級計劃，此外，還有26%的用戶表示還沒做好決定。 對於這一調查結果，個人倒不會感到太大的意外。畢竟就目前的爆料的信息來看，iPhone 13相較於上一代並不會太多的提升，很可能只是將後置模組中的鏡頭改變了擺放位置，劉海屏縮小一些，並上全新的A15芯片。至於大家尤爲關心的120Hz高刷屏和大電池，大概率也只會在iPhone 13 Pro/ Pro Max身上出現。 此外，據烏克蘭人稱，iPhone 13系列將提供新的粉紅色、黑色和青銅色，存儲選項將與iPhone 12相同，除了 5.4 英寸和 6.1 英寸標準型號沒有 256GB 存儲選項之外被91mobiles發現的電子商務網站“KTC”聲稱已經透露了即將推出的設備的配置選項。 MacRumors 對黑色、青銅色和粉紅色 iPhone 13 型號的渲染。在iPhone 13迷你和iPhone 13顯然將繼續在六個顏色可供選擇：黑色，藍色，紫色，粉色，白色，和PRODUCT（RED）。這意味着粉紅色將取代 iPhone 12 陣容中的綠色。 另一方面，據稱iPhone 13 Pro和iPhone 13 Pro Max將繼續提供四種顏色選擇：黑色、銀色、金色和青銅色。這意味着黑色將取代iPhone 12 Pro系列中的石墨，而青銅色將取代太平洋藍。 再加上目前iPhone 12已經支持了5G網絡，所以對於iPhone 12用戶而言，新機確實談不上有太大的吸引力。下面","text":"隨着9月15日的蘋果特別活動日一天天的臨近，近期網上也涌現出諸多關於iPhone 13的信息。除了有新機的配置、價格爆料之外，最近還有媒體對iPhone用戶是否有升級iPhone 13的願意做了一期調查。據悉，該調查是由Savings開展，收集1500名iPhone用戶的意向。 根據調查結果顯示：其中僅有10%的用戶計劃入手iPhone 13，有着64%的用戶沒有升級計劃，此外，還有26%的用戶表示還沒做好決定。 對於這一調查結果，個人倒不會感到太大的意外。畢竟就目前的爆料的信息來看，iPhone 13相較於上一代並不會太多的提升，很可能只是將後置模組中的鏡頭改變了擺放位置，劉海屏縮小一些，並上全新的A15芯片。至於大家尤爲關心的120Hz高刷屏和大電池，大概率也只會在iPhone 13 Pro/ Pro Max身上出現。 此外，據烏克蘭人稱，iPhone 13系列將提供新的粉紅色、黑色和青銅色，存儲選項將與iPhone 12相同，除了 5.4 英寸和 6.1 英寸標準型號沒有 256GB 存儲選項之外被91mobiles發現的電子商務網站“KTC”聲稱已經透露了即將推出的設備的配置選項。 MacRumors 對黑色、青銅色和粉紅色 iPhone 13 型號的渲染。在iPhone 13迷你和iPhone 13顯然將繼續在六個顏色可供選擇：黑色，藍色，紫色，粉色，白色，和PRODUCT（RED）。這意味着粉紅色將取代 iPhone 12 陣容中的綠色。 另一方面，據稱iPhone 13 Pro和iPhone 13 Pro Max將繼續提供四種顏色選擇：黑色、銀色、金色和青銅色。這意味着黑色將取代iPhone 12 Pro系列中的石墨，而青銅色將取代太平洋藍。 再加上目前iPhone 12已經支持了5G網絡，所以對於iPhone 12用戶而言，新機確實談不上有太大的吸引力。下面","images":[{"img":"https://static.tigerbbs.com/2fe570d3643c505741c38c94d03cd853","width":"400","height":"225"},{"img":"https://static.tigerbbs.com/439a10342ff65ee248adad23544bb2bd","width":"640","height":"950"},{"img":"https://static.tigerbbs.com/3be3145812aabd30a8e638523e3e3ef3","width":"640","height":"599"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883298049","isVote":2,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"vote":{"id":1557,"gmtBegin":1631241605737,"gmtEnd":1631759961831,"type":1,"upper":1,"title":"發佈會之後，你會換iPhone 13嗎？","choices":[{"id":5751,"sort":1,"name":"Yes！","userSize":136,"voted":false},{"id":5752,"sort":2,"name":"No！","userSize":234,"voted":false}]},"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889543403,"gmtCreate":1631162215002,"gmtModify":1676530484238,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889543403","repostId":"1194004223","repostType":4,"repost":{"id":"1194004223","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631107719,"share":"https://ttm.financial/m/news/1194004223?lang=en_US&edition=fundamental","pubTime":"2021-09-08 21:28","market":"us","language":"en","title":"U.S. stock market opens slightly lower on Wednesday as investors await Beige book","url":"https://stock-news.laohu8.com/highlight/detail?id=1194004223","media":"Tiger Newspress","summary":"(Sept 8) U.S. stock market opens slightly lower on Wednesday as investors await Beige book.\nThe Dow ","content":"<p>(Sept 8)&nbsp;U.S. stock market opens slightly lower on Wednesday as investors await Beige book.</p>\n<p>The Dow Jones Industrial Average rose just 3 points. The S&amp;P 500 traded around the flat line. The Nasdaq Composite fell 0.4% after closing at a record on Tuesday.</p>\n<p>Some&nbsp;China concepts stocks&nbsp;fell&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/0f5299ed6b4d0296e027fa821eec6ccb\" tg-width=\"279\" tg-height=\"853\" referrerpolicy=\"no-referrer\"></p>\n<p><b><a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> surged over 70%&nbsp;&nbsp;in&nbsp;early&nbsp;trading.&nbsp;Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B.</p>\n<p><b><a href=\"https://laohu8.com/S/SFTBY\">Softbank Group Corp</a></b> rose for second day&nbsp;as investors hope for buybacks.&nbsp;“We think a buyback is now likely,” Citigroup Inc. analyst Mitsunobu Tsuruo wrote in a note on Wednesday, after the announcement of the Deutsche Telekom deal that will see SoftBank acquire 4.5% of the German carrier as well as sell part of its stake in T-Mobile US Inc.</p>\n<p>That deal should eventually cash out over 1.45 trillion yen ($13.1 billion) in total that may be allotted to a “major share buyback,” Tsuruo wrote.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock market opens slightly lower on Wednesday as investors await Beige book</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock market opens slightly lower on Wednesday as investors await Beige book\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-08 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 8)&nbsp;U.S. stock market opens slightly lower on Wednesday as investors await Beige book.</p>\n<p>The Dow Jones Industrial Average rose just 3 points. The S&amp;P 500 traded around the flat line. The Nasdaq Composite fell 0.4% after closing at a record on Tuesday.</p>\n<p>Some&nbsp;China concepts stocks&nbsp;fell&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/0f5299ed6b4d0296e027fa821eec6ccb\" tg-width=\"279\" tg-height=\"853\" referrerpolicy=\"no-referrer\"></p>\n<p><b><a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> surged over 70%&nbsp;&nbsp;in&nbsp;early&nbsp;trading.&nbsp;Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B.</p>\n<p><b><a href=\"https://laohu8.com/S/SFTBY\">Softbank Group Corp</a></b> rose for second day&nbsp;as investors hope for buybacks.&nbsp;“We think a buyback is now likely,” Citigroup Inc. analyst Mitsunobu Tsuruo wrote in a note on Wednesday, after the announcement of the Deutsche Telekom deal that will see SoftBank acquire 4.5% of the German carrier as well as sell part of its stake in T-Mobile US Inc.</p>\n<p>That deal should eventually cash out over 1.45 trillion yen ($13.1 billion) in total that may be allotted to a “major share buyback,” Tsuruo wrote.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF","SFTBY":"软银集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194004223","content_text":"(Sept 8) U.S. stock market opens slightly lower on Wednesday as investors await Beige book.\nThe Dow Jones Industrial Average rose just 3 points. The S&P 500 traded around the flat line. The Nasdaq Composite fell 0.4% after closing at a record on Tuesday.\nSome China concepts stocks fell in early trading.\n\nKadmon surged over 70%  in early trading. Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B.\nSoftbank Group Corp rose for second day as investors hope for buybacks. “We think a buyback is now likely,” Citigroup Inc. analyst Mitsunobu Tsuruo wrote in a note on Wednesday, after the announcement of the Deutsche Telekom deal that will see SoftBank acquire 4.5% of the German carrier as well as sell part of its stake in T-Mobile US Inc.\nThat deal should eventually cash out over 1.45 trillion yen ($13.1 billion) in total that may be allotted to a “major share buyback,” Tsuruo wrote.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,"SPY":0.9,".DJI":0.9,"SFTBY":0.9}},"isVote":1,"tweetType":1,"viewCount":791,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818694644,"gmtCreate":1630400920088,"gmtModify":1676530292564,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818694644","repostId":"2163888743","repostType":2,"repost":{"id":"2163888743","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1630320528,"share":"https://ttm.financial/m/news/2163888743?lang=en_US&edition=fundamental","pubTime":"2021-08-30 18:48","market":"us","language":"en","title":"Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2163888743","media":"T-Reuters","summary":"Pfizer Inc :Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy O","content":"<html><body><p>Pfizer Inc <pfe.n>:Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.</pfe.n></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPositive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-08-30 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Pfizer Inc <pfe.n>:Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.</pfe.n></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LABP":"Landos Biopharma, Inc.","SANA":"Sana Biotechnology, Inc.","CGEM":"Cullinan Therapeutics","LHDX":"Lucira Health, Inc.","PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163888743","content_text":"Pfizer Inc :Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.","news_type":1,"symbols_score_info":{"APR":0.86,"SANA":0.86,"LHDX":0.86,"CGEM":0.86,"LABP":0.86,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":896,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818692670,"gmtCreate":1630400818990,"gmtModify":1676530292507,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818692670","repostId":"1131957400","repostType":4,"isVote":1,"tweetType":1,"viewCount":845,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818692117,"gmtCreate":1630400805739,"gmtModify":1676530292507,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818692117","repostId":"2163858570","repostType":4,"isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818696564,"gmtCreate":1630400784158,"gmtModify":1676530292491,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818696564","repostId":"1147371212","repostType":4,"isVote":1,"tweetType":1,"viewCount":694,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836556621,"gmtCreate":1629509514763,"gmtModify":1676530061239,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836556621","repostId":"2161745179","repostType":4,"repost":{"id":"2161745179","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629500040,"share":"https://ttm.financial/m/news/2161745179?lang=en_US&edition=fundamental","pubTime":"2021-08-21 06:54","market":"us","language":"en","title":"Pfizer, BioNTech stocks rises on report FDA could fully approve COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2161745179","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and U.S. shares of BioNTech SE (BNTX) rose in the extended session Friday follow","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and U.S. shares of <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) rose in the extended session Friday following a report that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week. Pfizer shares rose more than 2% after hours, following a 0.2% decline to close at $48.72, and BioNTech's ADRs rallied more than 5%, following a 5.1% gain to close at $348.68. Late Friday, The New York Times reported targeting the delta variant of the virus.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech stocks rises on report FDA could fully approve COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech stocks rises on report FDA could fully approve COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-21 06:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and U.S. shares of <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) rose in the extended session Friday following a report that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week. Pfizer shares rose more than 2% after hours, following a 0.2% decline to close at $48.72, and BioNTech's ADRs rallied more than 5%, following a 5.1% gain to close at $348.68. Late Friday, The New York Times reported targeting the delta variant of the virus.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161745179","content_text":"Pfizer Inc. $(PFE)$ and U.S. shares of BioNTech SE (BNTX) rose in the extended session Friday following a report that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week. Pfizer shares rose more than 2% after hours, following a 0.2% decline to close at $48.72, and BioNTech's ADRs rallied more than 5%, following a 5.1% gain to close at $348.68. Late Friday, The New York Times reported targeting the delta variant of the virus.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":824,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836689210,"gmtCreate":1629475692930,"gmtModify":1676530055179,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"???","listText":"???","text":"???","images":[{"img":"https://static.tigerbbs.com/97120d9c737d0054e0f1106bf2f79155","width":"1080","height":"2282"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836689210","isVote":1,"tweetType":1,"viewCount":770,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":176613508,"gmtCreate":1626879490604,"gmtModify":1703479886641,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176613508","repostId":"1107219983","repostType":4,"repost":{"id":"1107219983","kind":"news","pubTimestamp":1626858926,"share":"https://ttm.financial/m/news/1107219983?lang=en_US&edition=fundamental","pubTime":"2021-07-21 17:15","market":"us","language":"en","title":"Here Is The One-Word Reason Why JPMorgan Just Raised Its S&P Target To 4,600","url":"https://stock-news.laohu8.com/highlight/detail?id=1107219983","media":"zerohedge","summary":"Mid-cycle?Late-cycle? Nope: according to the latest note published overnight from JPMorgan head glob","content":"<p>Mid-cycle?Late-cycle? Nope: according to the latest note published overnight from JPMorgan head global equity strategist Dubravko Lakos-Bujas, \"even though equity leadership and bonds are trading as if the global economy is entering late cycle,<b>our research suggests the recovery is still in early-cycle</b>and gradually transitioning towards mid-cycle.\" And echoing his JPM colleague and fellow Croat, Marko Kolanovic, who yesterdayadvised clients to stop freaking out about the delta variant(advise which markets are taking to heart today), Dubravko writes that the largest commercial bank remains \"constructive on equities and see the latest round of growth and slowdown fears premature and overblown.\"</p>\n<p><img src=\"https://static.tigerbbs.com/52b0923c42b8b316b85e56a776fa3337\" tg-width=\"1132\" tg-height=\"1215\" width=\"100%\" height=\"auto\">Elaborating on why he is sanguine about the current Delta case breakout, Lakos-Bujas writes that \"we remain of the view that this latest wave will not derail the broader reopening process. While cases have gone up, deaths / hospitalizations remain low and stable due to broadening vaccination rollout and self-immunity from prior waves.\"</p>\n<p><img src=\"https://static.tigerbbs.com/d396ca943f750f3a3bcb38e01a53cbdf\" tg-width=\"772\" tg-height=\"546\" width=\"100%\" height=\"auto\">The strategist then argues that \"reopening of the economy is not an event but rather a process, which in our opinion is still not priced-in, and especially not now given recent market moves. For instance, an increasing number of reopening stocks are now down 30-50% from 1Q21 highs (i.e. travel, cruise lines, oil) and some have reversed back to last year June levels when COVID-19 uncertainty and economic setup were vastly worse than today.\"</p>\n<p>Given the above, JPM sees \"increasingly compelling\" risk/reward for the reopening theme, which can be expressed through Consumer Recovery (JPAMCONR &lt;Index&gt;), Domestic Recovery (JPAMCRDB &lt;Index&gt;) and International Recovery (JPAMCRIB &lt;Index&gt;) baskets, see Fig 1.\" Additionally, JPm argues that global mobility remains nascent and its normalization will continue to release pent-up demand, while tight inventories and new orders bode positively for global growth.</p>\n<p><img src=\"https://static.tigerbbs.com/dc9c52172685e208ffe19abe53233205\" tg-width=\"958\" tg-height=\"959\" width=\"100%\" height=\"auto\">Combining all this bullishness,<b>the JPM equity strategist is revising his EPS estimates higher by an additional $5 to $205 for 2021 and raises the bank's long-held 2021 year-end price target of 4,400 to 4,600, due to the following considerations:</b></p>\n<blockquote>\n At a thematic/sector level, the risk/reward for reopening stocks has improved significantly with the recent pullback creating many unusually attractive opportunities for investors to re-enter various parts of the cyclical cohort. Consumer Discretionary (i.e. Retail, Travel &amp; Leisure), Semis, Banks and Energy are strong buys at current levels. For instance,\n <b>large-cap Energy is now trading at a ~10% FCF yield and a &gt;8% FCF/EV yield at $70 Brent in 2022, with leverage that is &lt;1x</b>. The sector has increasing potential for a sharp short squeeze and move higher, given its extreme disconnect from oil fundamentals (i.e. widest in 30+ years, Figure 10). In addition, our Semiconductor research argues that we are only 30-40% of the way into&nbsp; the current semiconductor upcycle and expect strong Y/Y growth into next year with positive EPS revisions for the next 3-4 quarters. Supply will likely remain tight into 2022, while demand remains strong (20-40% above companies’ ability to supply), thus this supply demand imbalance will persist through 2021. Although customers are responding to tight supply with higher than needed orders, ongoing supply tightness is limiting fulfillment. In fact, JPM expects channel and customer inventories to decline Q/Q again in the just completed June quarter.\n</blockquote>\n<p>Looking at the fundamentals, JPM predicts that S&amp;P 500 gains should also be supported by strong earnings growth and capital return until 2023,<b>and is why JPM is adjusting its above consensus S&amp;P 500 EPS by another $5 for 2022 to $230 (consensus $214) and 2023 to $250 (consensus $233).</b></p>\n<blockquote>\n This revision is largely due to global reopening which is delayed and bound to release further pent-up demand, inventory replenishment, rising profitability for Energy companies, and ongoing policy actions (childcare, infrastructure, etc). We expect cumulative revenue growth of ~30% by 2023 relative to pre-COVID (FY 2019), ~150bp net income margin expansion to a record high at over 13%, and gross buybacks nearing an annual pace of ~$1t during this period.\n</blockquote>\n<p>While all sectors are expected to contribute to earnings growth, JPM expects reflation sensitive sectors (Commodities, Financials, Industrials) and Consumer to do the heaviest lifting in the coming quarters in terms of beats and revisions.</p>\n<p>Putting it all together, Lakos-Bujas says that \"<b>considering this outlook for earnings and shareholder return, we are raising our Price Target to 4,600 for year-end 2021.\"</b></p>\n<p>But while any first year strategist can goalseek a fundamentally bullish narrative and chart it, as JPM has done below...</p>\n<p><img src=\"https://static.tigerbbs.com/41e87174356d968c69893caff66745e0\" tg-width=\"1072\" tg-height=\"1304\" width=\"100%\" height=\"auto\">... there is a very specific reason behind JPM's bullish reversal:<b>the coming surge in buybacks which will result in a boom in shareholder returns,</b>or as Dubravko notes, \"corporates have already increased gross buybacks from pandemic era low of $525b (trailing twelve months as of 1Q21) to an annualized run rate of ~$775b YTD and should surpass previous record of ~$850b (as of 1Q19).\"</p>\n<p><img src=\"https://static.tigerbbs.com/3b09d295af263e87277eaffbda47bb7c\" tg-width=\"1076\" tg-height=\"435\" width=\"100%\" height=\"auto\">In practical terms, JPM expects a sharp drop in the S&amp;P's share count in the next 24 months as the buyback-facilitated slow-motion LBO continues.</p>\n<p><img src=\"https://static.tigerbbs.com/ae94ad29f188e3aac5cdf92b9df65fc3\" tg-width=\"1048\" tg-height=\"396\" width=\"100%\" height=\"auto\">Some more details below on the one biggest catalyst behind JPM's SPX price target hike:</p>\n<blockquote>\n <b>Expecting a boom in shareholder return led by buybacks.</b>Buybacks are reemerging as a key theme with net buyback activity significantly improving this year after bottoming in 2Q20. Corporate buyback announcements, typically a leading indicator of buyback execution activity and corporate confidence, have already well-exceeded 2020 levels ($431B YTD vs. $307B 2020, see Figure 25). In fact,\n <b>the rebound in announcement activity is similar to the surge post-TCJA (see Figure 23) which is tracking towards and it is likely to easily surpass ~$650B by year-end and likely to see rolling 12-month announcements surpass prior record level of ~$1T.</b>Historically, buyback announcements have been concentrated within Technology and Financials. However, YTD we are seeing strong announcement activity from Communications as well (driven by GOOGL ~$50B in Apr). As a reminder, ~$90B of Tech’s $133B in announcements YTD is supported by AAPL and ~$25B of Financials' ~$92B is supported by BAC.\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/774d4e9c2550b27c62d10733947c8de4\" tg-width=\"1077\" tg-height=\"384\" width=\"100%\" height=\"auto\">With the June 30th lifting of pandemic era restriction on US Banks,<b>we could see some further pick-up in buyback announcements.</b>Dry powder (i.e. announced repurchase programs not yet executed) levels have been recovering to pre-pandemic levels (~$658B, see Figure 27) as executions have been relatively slower to rebound but should show a material sequential growth in the coming quarters. With record profit margins (~13% in 2022 vs ~11.5% in 2019), bloated cash levels of $2.0T ex-financials (vs. $1.6T pre- COVID), and lower high grade debt yields (JULI at 2.6% now, vs 3.3% prepandemic),<b>we are expecting a boom in buyback activity over the next year.</b>Gross buybacks should surpass the prior executed high of $850b.</p>\n<p><img src=\"https://static.tigerbbs.com/053354e7e2fc9ea74585b437e0d77f78\" tg-width=\"1076\" tg-height=\"415\" width=\"100%\" height=\"auto\">In summary,<i>assuming $875b in buybacks and dividend income of $575 over the next year,</i>JPM calculates that<b>the expected shareholder yield is 3.9%.</b>This, as Dubravko concludes, \"is a significant cross-asset valuation support for equities at a time when 10yr US bonds are yielding 1.2% and $13 trillion of global debt has a negative yield.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here Is The One-Word Reason Why JPMorgan Just Raised Its S&P Target To 4,600</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere Is The One-Word Reason Why JPMorgan Just Raised Its S&P Target To 4,600\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 17:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/here-one-word-reason-why-jpmorgan-just-raised-its-sp-target-4600><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mid-cycle?Late-cycle? Nope: according to the latest note published overnight from JPMorgan head global equity strategist Dubravko Lakos-Bujas, \"even though equity leadership and bonds are trading as ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/here-one-word-reason-why-jpmorgan-just-raised-its-sp-target-4600\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.zerohedge.com/markets/here-one-word-reason-why-jpmorgan-just-raised-its-sp-target-4600","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107219983","content_text":"Mid-cycle?Late-cycle? Nope: according to the latest note published overnight from JPMorgan head global equity strategist Dubravko Lakos-Bujas, \"even though equity leadership and bonds are trading as if the global economy is entering late cycle,our research suggests the recovery is still in early-cycleand gradually transitioning towards mid-cycle.\" And echoing his JPM colleague and fellow Croat, Marko Kolanovic, who yesterdayadvised clients to stop freaking out about the delta variant(advise which markets are taking to heart today), Dubravko writes that the largest commercial bank remains \"constructive on equities and see the latest round of growth and slowdown fears premature and overblown.\"\nElaborating on why he is sanguine about the current Delta case breakout, Lakos-Bujas writes that \"we remain of the view that this latest wave will not derail the broader reopening process. While cases have gone up, deaths / hospitalizations remain low and stable due to broadening vaccination rollout and self-immunity from prior waves.\"\nThe strategist then argues that \"reopening of the economy is not an event but rather a process, which in our opinion is still not priced-in, and especially not now given recent market moves. For instance, an increasing number of reopening stocks are now down 30-50% from 1Q21 highs (i.e. travel, cruise lines, oil) and some have reversed back to last year June levels when COVID-19 uncertainty and economic setup were vastly worse than today.\"\nGiven the above, JPM sees \"increasingly compelling\" risk/reward for the reopening theme, which can be expressed through Consumer Recovery (JPAMCONR <Index>), Domestic Recovery (JPAMCRDB <Index>) and International Recovery (JPAMCRIB <Index>) baskets, see Fig 1.\" Additionally, JPm argues that global mobility remains nascent and its normalization will continue to release pent-up demand, while tight inventories and new orders bode positively for global growth.\nCombining all this bullishness,the JPM equity strategist is revising his EPS estimates higher by an additional $5 to $205 for 2021 and raises the bank's long-held 2021 year-end price target of 4,400 to 4,600, due to the following considerations:\n\n At a thematic/sector level, the risk/reward for reopening stocks has improved significantly with the recent pullback creating many unusually attractive opportunities for investors to re-enter various parts of the cyclical cohort. Consumer Discretionary (i.e. Retail, Travel & Leisure), Semis, Banks and Energy are strong buys at current levels. For instance,\n large-cap Energy is now trading at a ~10% FCF yield and a >8% FCF/EV yield at $70 Brent in 2022, with leverage that is <1x. The sector has increasing potential for a sharp short squeeze and move higher, given its extreme disconnect from oil fundamentals (i.e. widest in 30+ years, Figure 10). In addition, our Semiconductor research argues that we are only 30-40% of the way into  the current semiconductor upcycle and expect strong Y/Y growth into next year with positive EPS revisions for the next 3-4 quarters. Supply will likely remain tight into 2022, while demand remains strong (20-40% above companies’ ability to supply), thus this supply demand imbalance will persist through 2021. Although customers are responding to tight supply with higher than needed orders, ongoing supply tightness is limiting fulfillment. In fact, JPM expects channel and customer inventories to decline Q/Q again in the just completed June quarter.\n\nLooking at the fundamentals, JPM predicts that S&P 500 gains should also be supported by strong earnings growth and capital return until 2023,and is why JPM is adjusting its above consensus S&P 500 EPS by another $5 for 2022 to $230 (consensus $214) and 2023 to $250 (consensus $233).\n\n This revision is largely due to global reopening which is delayed and bound to release further pent-up demand, inventory replenishment, rising profitability for Energy companies, and ongoing policy actions (childcare, infrastructure, etc). We expect cumulative revenue growth of ~30% by 2023 relative to pre-COVID (FY 2019), ~150bp net income margin expansion to a record high at over 13%, and gross buybacks nearing an annual pace of ~$1t during this period.\n\nWhile all sectors are expected to contribute to earnings growth, JPM expects reflation sensitive sectors (Commodities, Financials, Industrials) and Consumer to do the heaviest lifting in the coming quarters in terms of beats and revisions.\nPutting it all together, Lakos-Bujas says that \"considering this outlook for earnings and shareholder return, we are raising our Price Target to 4,600 for year-end 2021.\"\nBut while any first year strategist can goalseek a fundamentally bullish narrative and chart it, as JPM has done below...\n... there is a very specific reason behind JPM's bullish reversal:the coming surge in buybacks which will result in a boom in shareholder returns,or as Dubravko notes, \"corporates have already increased gross buybacks from pandemic era low of $525b (trailing twelve months as of 1Q21) to an annualized run rate of ~$775b YTD and should surpass previous record of ~$850b (as of 1Q19).\"\nIn practical terms, JPM expects a sharp drop in the S&P's share count in the next 24 months as the buyback-facilitated slow-motion LBO continues.\nSome more details below on the one biggest catalyst behind JPM's SPX price target hike:\n\nExpecting a boom in shareholder return led by buybacks.Buybacks are reemerging as a key theme with net buyback activity significantly improving this year after bottoming in 2Q20. Corporate buyback announcements, typically a leading indicator of buyback execution activity and corporate confidence, have already well-exceeded 2020 levels ($431B YTD vs. $307B 2020, see Figure 25). In fact,\n the rebound in announcement activity is similar to the surge post-TCJA (see Figure 23) which is tracking towards and it is likely to easily surpass ~$650B by year-end and likely to see rolling 12-month announcements surpass prior record level of ~$1T.Historically, buyback announcements have been concentrated within Technology and Financials. However, YTD we are seeing strong announcement activity from Communications as well (driven by GOOGL ~$50B in Apr). As a reminder, ~$90B of Tech’s $133B in announcements YTD is supported by AAPL and ~$25B of Financials' ~$92B is supported by BAC.\n\nWith the June 30th lifting of pandemic era restriction on US Banks,we could see some further pick-up in buyback announcements.Dry powder (i.e. announced repurchase programs not yet executed) levels have been recovering to pre-pandemic levels (~$658B, see Figure 27) as executions have been relatively slower to rebound but should show a material sequential growth in the coming quarters. With record profit margins (~13% in 2022 vs ~11.5% in 2019), bloated cash levels of $2.0T ex-financials (vs. $1.6T pre- COVID), and lower high grade debt yields (JULI at 2.6% now, vs 3.3% prepandemic),we are expecting a boom in buyback activity over the next year.Gross buybacks should surpass the prior executed high of $850b.\nIn summary,assuming $875b in buybacks and dividend income of $575 over the next year,JPM calculates thatthe expected shareholder yield is 3.9%.This, as Dubravko concludes, \"is a significant cross-asset valuation support for equities at a time when 10yr US bonds are yielding 1.2% and $13 trillion of global debt has a negative yield.\"","news_type":1,"symbols_score_info":{".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176637628,"gmtCreate":1626879338964,"gmtModify":1703479882704,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176637628","repostId":"1182009211","repostType":4,"repost":{"id":"1182009211","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626876025,"share":"https://ttm.financial/m/news/1182009211?lang=en_US&edition=fundamental","pubTime":"2021-07-21 22:00","market":"us","language":"en","title":"Cryptocurrency-related stocks soar in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1182009211","media":"Tiger Newspress","summary":"(July 21) Cryptocurrency-related stocks soar in morning trading. \nOn day after sliding below $30,000","content":"<p>(July 21)&nbsp;Cryptocurrency-related stocks soar in morning trading.&nbsp;</p>\n<p>On day after sliding below $30,000, a key support level which many said has to hold, it did just that with bitcoin storming higher and back over $31,000.</p>\n<p><img src=\"https://static.tigerbbs.com/96ba84b633e0ac3f409f8c463cd88beb\" tg-width=\"310\" tg-height=\"366\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/b1ff2661c20fa3335bbd359f86b5e594\" tg-width=\"687\" tg-height=\"733\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cryptocurrency-related stocks soar in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCryptocurrency-related stocks soar in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-21 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(July 21)&nbsp;Cryptocurrency-related stocks soar in morning trading.&nbsp;</p>\n<p>On day after sliding below $30,000, a key support level which many said has to hold, it did just that with bitcoin storming higher and back over $31,000.</p>\n<p><img src=\"https://static.tigerbbs.com/96ba84b633e0ac3f409f8c463cd88beb\" tg-width=\"310\" tg-height=\"366\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/b1ff2661c20fa3335bbd359f86b5e594\" tg-width=\"687\" tg-height=\"733\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182009211","content_text":"(July 21) Cryptocurrency-related stocks soar in morning trading. \nOn day after sliding below $30,000, a key support level which many said has to hold, it did just that with bitcoin storming higher and back over $31,000.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176658439,"gmtCreate":1626881619821,"gmtModify":1703479945647,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"OMG ?","listText":"OMG ?","text":"OMG ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176658439","repostId":"1156292040","repostType":4,"repost":{"id":"1156292040","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626880084,"share":"https://ttm.financial/m/news/1156292040?lang=en_US&edition=fundamental","pubTime":"2021-07-21 23:08","market":"us","language":"en","title":"Airline stocks, Cruise Stocks rally continues in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1156292040","media":"Tiger Newspress","summary":"(July 21) Airline stocks, Cruise Stocks rally continues in morning trading.\nShares of Carnival  rose","content":"<p>(July&nbsp;21)&nbsp;Airline stocks, Cruise Stocks rally continues in morning trading.<img src=\"https://static.tigerbbs.com/552c4c7cf72c26141391a54bd44731bc\" tg-width=\"307\" tg-height=\"364\" width=\"100%\" height=\"auto\"></p>\n<p>Shares of&nbsp;<a href=\"https://laohu8.com/S/CCL\">Carnival</a> &nbsp;rose&nbsp;over&nbsp;3%&nbsp;in&nbsp;premarket trading,&nbsp;after&nbsp;the company said it plans to resume guest cruise operations across eight of its cruise line brands by the end of 2021. This would bring Carnival's total operating capacity to nearly 75% by the end of 2021.</p>\n<p>A total of 54 ships across AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, Princess Cruises, P&amp;O Cruises, and Seabourn plan to resume operations by the end of 2021.&nbsp;Carnival Cruise Line plans to return its full fleet to service this year, which would bring a total of 63 ships back to operations in 2021.</p>\n<p>Carnival stock has rebounded 32% over the last year but tumbled in June&nbsp;as it ran into some hurdles with the state of Florida's pushback over COVID-19 vaccine mandates, which Carnival views as important to making passengers feel safe on board.Cruise stockshave come under more selling pressure in July over a recent spike in COVID-19 cases.</p>\n<p>Nonetheless, the updated roadmap on returning to normal operations gives investors some near-term visibility on Carnival's recovery. There seems to be tremendous pent-up demand for people to travel again. Carnival announced in early July that a 40-night winter sun Caribbean cruise on P&amp;O Cruises sold out in the first day.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airline stocks, Cruise Stocks rally continues in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirline stocks, Cruise Stocks rally continues in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-21 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(July&nbsp;21)&nbsp;Airline stocks, Cruise Stocks rally continues in morning trading.<img src=\"https://static.tigerbbs.com/552c4c7cf72c26141391a54bd44731bc\" tg-width=\"307\" tg-height=\"364\" width=\"100%\" height=\"auto\"></p>\n<p>Shares of&nbsp;<a href=\"https://laohu8.com/S/CCL\">Carnival</a> &nbsp;rose&nbsp;over&nbsp;3%&nbsp;in&nbsp;premarket trading,&nbsp;after&nbsp;the company said it plans to resume guest cruise operations across eight of its cruise line brands by the end of 2021. This would bring Carnival's total operating capacity to nearly 75% by the end of 2021.</p>\n<p>A total of 54 ships across AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, Princess Cruises, P&amp;O Cruises, and Seabourn plan to resume operations by the end of 2021.&nbsp;Carnival Cruise Line plans to return its full fleet to service this year, which would bring a total of 63 ships back to operations in 2021.</p>\n<p>Carnival stock has rebounded 32% over the last year but tumbled in June&nbsp;as it ran into some hurdles with the state of Florida's pushback over COVID-19 vaccine mandates, which Carnival views as important to making passengers feel safe on board.Cruise stockshave come under more selling pressure in July over a recent spike in COVID-19 cases.</p>\n<p>Nonetheless, the updated roadmap on returning to normal operations gives investors some near-term visibility on Carnival's recovery. There seems to be tremendous pent-up demand for people to travel again. Carnival announced in early July that a 40-night winter sun Caribbean cruise on P&amp;O Cruises sold out in the first day.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UAL":"联合大陆航空","SAVE":"Spirit Airlines","NCLH":"挪威邮轮","DAL":"达美航空","CCL":"嘉年华邮轮","LUV":"西南航空","BA":"波音","AAL":"美国航空","RCL":"皇家加勒比邮轮"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156292040","content_text":"(July 21) Airline stocks, Cruise Stocks rally continues in morning trading.\nShares of Carnival  rose over 3% in premarket trading, after the company said it plans to resume guest cruise operations across eight of its cruise line brands by the end of 2021. This would bring Carnival's total operating capacity to nearly 75% by the end of 2021.\nA total of 54 ships across AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, Princess Cruises, P&O Cruises, and Seabourn plan to resume operations by the end of 2021. Carnival Cruise Line plans to return its full fleet to service this year, which would bring a total of 63 ships back to operations in 2021.\nCarnival stock has rebounded 32% over the last year but tumbled in June as it ran into some hurdles with the state of Florida's pushback over COVID-19 vaccine mandates, which Carnival views as important to making passengers feel safe on board.Cruise stockshave come under more selling pressure in July over a recent spike in COVID-19 cases.\nNonetheless, the updated roadmap on returning to normal operations gives investors some near-term visibility on Carnival's recovery. There seems to be tremendous pent-up demand for people to travel again. Carnival announced in early July that a 40-night winter sun Caribbean cruise on P&O Cruises sold out in the first day.","news_type":1,"symbols_score_info":{"LUV":0.9,"DAL":0.9,"NCLH":0.9,"SAVE":0.9,"RCL":0.9,"UAL":0.9,"CCL":0.9,"BA":0.9,"AAL":0.9}},"isVote":1,"tweetType":1,"viewCount":980,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187705275,"gmtCreate":1623763803697,"gmtModify":1703818574909,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Pfizer hand up!","listText":"Pfizer hand up!","text":"Pfizer hand up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187705275","repostId":"1167457915","repostType":2,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://ttm.financial/m/news/1167457915?lang=en_US&edition=fundamental","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"NVAX":0.9,"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":704,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9991677984,"gmtCreate":1660833943250,"gmtModify":1676536407739,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"😁","listText":"😁","text":"😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991677984","repostId":"2260389489","repostType":4,"isVote":1,"tweetType":1,"viewCount":2666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9991648835,"gmtCreate":1660832404829,"gmtModify":1676536407315,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>View on Tesla Motors(TSLA)BullishBearish","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>View on Tesla Motors(TSLA)BullishBearish","text":"$Tesla Motors(TSLA)$View on Tesla Motors(TSLA)BullishBearish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9991648835","isVote":1,"tweetType":1,"viewCount":839,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818694644,"gmtCreate":1630400920088,"gmtModify":1676530292564,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818694644","repostId":"2163888743","repostType":2,"repost":{"id":"2163888743","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1630320528,"share":"https://ttm.financial/m/news/2163888743?lang=en_US&edition=fundamental","pubTime":"2021-08-30 18:48","market":"us","language":"en","title":"Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2163888743","media":"T-Reuters","summary":"Pfizer Inc :Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy O","content":"<html><body><p>Pfizer Inc <pfe.n>:Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.</pfe.n></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPositive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-08-30 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Pfizer Inc <pfe.n>:Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.</pfe.n></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LABP":"Landos Biopharma, Inc.","SANA":"Sana Biotechnology, Inc.","CGEM":"Cullinan Therapeutics","LHDX":"Lucira Health, Inc.","PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163888743","content_text":"Pfizer Inc :Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.","news_type":1,"symbols_score_info":{"APR":0.86,"SANA":0.86,"LHDX":0.86,"CGEM":0.86,"LABP":0.86,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":896,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890170375,"gmtCreate":1628088675697,"gmtModify":1703501085005,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Thank u","listText":"Thank u","text":"Thank u","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890170375","repostId":"1187165636","repostType":4,"isVote":1,"tweetType":1,"viewCount":817,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149428424,"gmtCreate":1625744621768,"gmtModify":1703747595630,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"Long termmmm","listText":"Long termmmm","text":"Long termmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149428424","repostId":"1140881081","repostType":4,"repost":{"id":"1140881081","kind":"news","pubTimestamp":1625714447,"share":"https://ttm.financial/m/news/1140881081?lang=en_US&edition=fundamental","pubTime":"2021-07-08 11:20","market":"hk","language":"en","title":"Why Apple Stock Climbed to a New High Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1140881081","media":"The motley fool","summary":"Shares of $Apple$rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.JPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.Chatterjee noted that Apple underperformed theS&P 500and$Nasdaq$in the first half of 202","content":"<p>What happened</p>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/AAPL\">Apple</a></b>(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.</p>\n<p>So what</p>\n<p>JPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.</p>\n<p>Chatterjee noted that Apple underperformed the<b>S&amp;P 500</b>and<b><a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a></b>in the first half of 2021. Yet he expects thetechtitan to post strong sales of both current and future models of the iPhone. Thus, Chatterjee posits that Apple's shares could generate strong gains for shareholders in the second half of the year ahead of the launch of the iPhone 13.</p>\n<p>Now what</p>\n<p>The recent rally in Apple's stock price suggests many investors agree with Chatterjee's bullish outlook. They're likely correct to do so. Robust iPhone volumes tend to also drive sales of Apple's high-margin services and fast-growing wearables revenue. So, if it does deliver blowout iPhone sales figures, Apple could enjoy an earnings bonanza later this year. This potential profit windfall, combined with Apple's bountiful share repurchases and steadily growing dividend, gives shareholders multiple ways to win.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple Stock Climbed to a New High Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple Stock Climbed to a New High Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Apple(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGD":"New Gold","09086":"华夏纳指-U","AAPL":"苹果","03086":"华夏纳指"},"source_url":"https://www.fool.com/investing/2021/07/07/why-apple-stock-climbed-to-a-new-high-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140881081","content_text":"What happened\nShares of Apple(NASDAQ:AAPL)rose 1.8% to a record closing high of $144.57 on Wednesday after a respected Wall Street investment bank issued bullish commentary on the popular tech stock.\nSo what\nJPMorgan analyst Samik Chatterjee reiterated his overweight rating on Apple's stock yesterday and boosted his share price forecast from $165 to $170. His new estimate implies potential gains to investors of roughly 18% in the coming year.\nChatterjee noted that Apple underperformed theS&P 500andNasdaqin the first half of 2021. Yet he expects thetechtitan to post strong sales of both current and future models of the iPhone. Thus, Chatterjee posits that Apple's shares could generate strong gains for shareholders in the second half of the year ahead of the launch of the iPhone 13.\nNow what\nThe recent rally in Apple's stock price suggests many investors agree with Chatterjee's bullish outlook. They're likely correct to do so. Robust iPhone volumes tend to also drive sales of Apple's high-margin services and fast-growing wearables revenue. So, if it does deliver blowout iPhone sales figures, Apple could enjoy an earnings bonanza later this year. This potential profit windfall, combined with Apple's bountiful share repurchases and steadily growing dividend, gives shareholders multiple ways to win.","news_type":1,"symbols_score_info":{"03086":0.9,"NGD":0.9,"AAPL":0.9,"09086":0.9}},"isVote":1,"tweetType":1,"viewCount":561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9996698018,"gmtCreate":1661155896736,"gmtModify":1676536463554,"author":{"id":"3586405989757525","authorId":"3586405989757525","name":"KhunSao","avatar":"https://static.tigerbbs.com/91ff42b55eed52cbbe5e0c6323d0e1d7","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586405989757525","idStr":"3586405989757525"},"themes":[],"htmlText":"🙂👍[Miser]&nbsp;","listText":"🙂👍[Miser]&nbsp;","text":"🙂👍[Miser]","images":[{"img":"https://community-static.tradeup.com/news/549c37ce0378c06a55072835b38ab1de","width":"1080","height":"1653"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9996698018","isVote":1,"tweetType":1,"viewCount":2302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}